Skip to main content

Advertisement

SpringerLink
Log in

Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis

  • Validation Studies
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Gastrointestinal (GI) involvement is the leading cause of morbidity with great impact on health-related quality of life (HRQOL) in patients with systemic sclerosis (SSc). The UCLA-GIT 2.0 is a disease-specific HRQOL instrument for the assessment of GI symptoms severity in patients with SSc. We evaluated reliability and validity of the Serbian version of UCLA-GIT 2.0 by assessing association of GI involvement and other disease manifestations in patients with SSc. UCLA-GIT 2.0 was adapted into Serbian and administered to 104 patients with SSc who had previously completed the SF-36 questionnaire. We evaluated the internal consistency reliability and associations between the UCLA-GIT 2.0 and SF-36 scales. Data from patients’ medical history were reviewed for other disease manifestations. UCLA-GIT 2.0 had acceptable reliability (defined as Cronbach’s alpha >0 .69) and the majority of hypothesized correlations with SF-36 scale scores were of moderate magnitude (coefficient ≥ 0.30). Active disease and pulmonary fibrosis were associated with higher GIT Total scale score (p < 0.05). Distension mostly correlated with HRQOL impairment (r = 0.70, p < 0.001). The Serbian version of the UCLA-GIT 2.0 questionnaire has acceptable reliability and validity for the assessment of GI involvement in patients with SSc. GI impairment is very frequent in patients with active SSc, as well in those with pulmonary fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lock G, Zeuner M, Lang B, Hein R, Scholmerich J, Holstege A (1997) Anorectal function in systemic sclerosis: correlation with esophageal dysfunction? Dis Colon Rectum 40:1328–1335

    Article  CAS  PubMed  Google Scholar 

  2. Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282

    Article  CAS  PubMed  Google Scholar 

  3. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444

    Article  CAS  PubMed  Google Scholar 

  4. Ebert EC (2008) Gastric and enteric involvement in progressive systemic sclerosis. J ClinGastroenterol 42:5–12

    Google Scholar 

  5. Ebert EC (2006) Esophageal disease in scleroderma. J ClinGastroenterol 40:769–775

    Google Scholar 

  6. Chiou AW, Lin JK, Wang FM (1989) Anorectal abnormalities in progressive systemic sclerosis. Dis Colon Rectum 32:417–421

    Article  CAS  PubMed  Google Scholar 

  7. Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S (1999) Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol 34:409–413

    Article  CAS  PubMed  Google Scholar 

  8. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD et al (2009) Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum 61:1257–1263

    Article  PubMed  PubMed Central  Google Scholar 

  9. Van Den Hoogen F, Khanna D, Fransen J et al (2013) 2013 Classification criteria for systemic sclerosis. An American College of Rheumathology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatism 65(11):2737–2747

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pignonne A, Scaletti C, MatucciCerinic M, Vasquez-Abad D, Del Papa N, Meroni PL et al (1998) Antiendothelial cell antibodies in systemic sclerosis: correlation with vascular involvement. Clin Exp Rheumatol 16:57:572–577

    Google Scholar 

  11. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’ Angelo S et al (2011) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598

    Article  Google Scholar 

  12. Khanna D, Hays RD, Park GS et al (2007) Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 57:1280–1286

    Article  PubMed  Google Scholar 

  13. Khanna D, Furst DE, Clementis PJ et al (2005) Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 32:832–840

    PubMed  Google Scholar 

  14. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P (2005) Principles of good practice for the translation and cultural adaptation process for patient reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 8:94–103

    Article  PubMed  Google Scholar 

  15. Yurdugül H (2008) Minimum sample size for Cronbach’s coefficient alpha: a Monte-Carlo study. Hacettepe Univ J Educ 35:397–405

  16. Bland JM, Altman DG (1997) Cronbach’s alpha. BMJ 314:572

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cohen J (2003) Applied multiple regression/correlation analyses for the behavioral sciences 3rd edn. Mahwah, NJ: Erlbaum L Associates. Xxviii, p 703

  18. ThouaNM, Bunce c, Brough G, Forbes A, Emmanuel AV, Denton C (2010) Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology 1770–1775

  19. Bae S, Allanore Y, Coustet B, Maranian P etKhanna D (2011) Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 29:S15–21

  20. Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G, Becciolini A, Ciavarella T, Marfia G, Murgo A, Scalone L, Ughi N, Zeni S; VERITAS study group (2015) Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clin Exp Rheumatol 33(4 Suppl 91):S55–S60 (Epub 2015 Aug 31)

  21. Meijs J, Pors D, Vliet Vlieland TP, Huizinga TW, Schouffoer AA (2014) Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 32(6 Suppl 86):S-41-8 (Epub 2014 Jun 30)

  22. Gorga M, Mihai C, Soare AM, Dobrotă R, Gherghe AM, Stoica V (2015) A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 33(4 Suppl 91):S61–S67 (Epub 2015 Aug 27)

  23. Lundberg AC, Akesson A, Akesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143–1148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Brown M, Teubner A, Shaffer J, Herrick AL (2000) Home parenteral nutrition-an effective and safe long term therapy for systemic sclerosis-related intestinal failure. Rheumatol 47:176–179

  25. Thonhofer R, Siegel C, Trummer M, Graninger W (2012) Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 32(1):165–168

    Article  PubMed  Google Scholar 

  26. Roman S, Hot A, Fabien N, Cordier JF, Miossec P, Ninet J et al (2010) Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis Esophagus Off J Int Soc Dis Esophagus/ISDE

  27. Tauber M, Avouac J, Benahmed A, Barbot L, Coustet B, Kahan A, Allanore Y (2014) Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol 32:S82–S87

  28. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L (2013) Clinical guideline: management of gastroparesis. Am J Gastroenterol 108(1):18–37

    Article  CAS  PubMed  Google Scholar 

  29. Soeters PB, Schols AMWJ (2009). Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care 12:487–494

  30. Gomez R, Conde J, Scotece M et al (2011) What‘s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7:528–536

    Article  CAS  PubMed  Google Scholar 

  31. Morley JE (2013) Pathophysiology of the anorexia of aging. Curr Opin Clin Nutr Metab Care 16:27–32

  32. Lakota K, Wei J, Carns M et al (2012) Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther 14:R102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Krause L, Becker MD, Brueckner CS, Bellinghausen CJ, Becker C, Schneider U et al (2010) Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 69:1951–1957

    Article  PubMed  Google Scholar 

  34. Nishimagi E, Tochimoto A, Kawaguchi Y et al (2007) Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 34:2050–2055

    PubMed  Google Scholar 

  35. Savarino E, Bazzica M, Zentilin P et al (2009) Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 179:408–413

    Article  PubMed  Google Scholar 

  36. Silver RM (1995) Interstitial lung disease of systemic sclerosis. Int Rev Immunol 12:281–291

    Article  CAS  PubMed  Google Scholar 

  37. Altman RD, MedsgerTAjr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413

    Article  CAS  PubMed  Google Scholar 

  38. Savarino E, Furnari M, De Bortoli N, Martinucci I, Bodini G, GhioMetSavarino V (2014) Gastrointestinal involvement in systemic sclerosis. Presse Med 43:e279–e291

    Article  PubMed  Google Scholar 

  39. Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A et a (1989) l. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 149:589–593

    Article  CAS  PubMed  Google Scholar 

  40. Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaiba A, Touchene B (2009) Esophageal dysmotility in scleroderma: a prospective study of 183 cases. Gastroentero lClin Biol 33:466–469

  41. Abu-Shakra M, Guillemini F, Lee P (1994) Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 24:29–39

    Article  CAS  PubMed  Google Scholar 

  42. Harper FE, Maricq HR, Turner RE, Lindman RW, LeRoy EC (1982) A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 72:883–888

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Rheumatology, Resavska 69, Belgrade, Serbia

    Ana Zekovic & Nemanja Damjanov

  2. Medical School, University of Belgrade, Belgrade, Serbia

    Nemanja Damjanov

Authors
  1. Ana Zekovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nemanja Damjanov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Zekovic.

Ethics declarations

Conflict of interest

Author Ana Zekovic and author Nemanja Damjanov declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zekovic, A., Damjanov, N. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis. Rheumatol Int 37, 735–741 (2017). https://doi.org/10.1007/s00296-017-3680-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-017-3680-y

Keywords

Search

Navigation